Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hybrid molecules: insights into plasminogen activator function.

M S Runge1, C Bode, E Haber

  • 1Emory University Division of Cardiology, Atlanta, GA 30322.

Molecular Biology & Medicine
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usability and feasibility of E-nergEYEze: a blended vision-specific E-health based cognitive behavioral therapy and self-management intervention to reduce fatigue in adults with visual impairment.

BMC health services research·2023
Same author

Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.

West African journal of medicine·2023
Same author

The effectiveness of motivational interviewing on adherence to wearing orthopedic shoes in people with diabetes at low-to-high risk of foot ulceration: A multicenter cluster-randomized controlled trial.

Diabetes research and clinical practice·2023
Same author

Attitudes and experiences towards the application of motivational interviewing by podiatrists working with people with diabetes at high-risk of developing foot ulcers: a mixed-methods study.

Journal of foot and ankle research·2022
Same author

Using motivational interviewing combined with digital shoe-fitting to improve adherence to wearing orthopedic shoes in people with diabetes at risk of foot ulceration: study protocol for a cluster-randomized controlled trial.

Trials·2021
Same author

Pro- and anti-inflammatory macrophages express a sub-type specific purinergic receptor profile.

Purinergic signalling·2021
Same journal

Modulation of cardiac genes by mechanical stress. The oncogene signalling hypothesis.

Molecular biology & medicine·1991
Same journal

Retroviral vector-mediated gene transfer into endothelial cells.

Molecular biology & medicine·1991
Same journal

Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.

Molecular biology & medicine·1991
Same journal

Strategies for administration of tissue plasminogen activator.

Molecular biology & medicine·1991
Same journal

Considerations affecting selection of thrombolytic agents.

Molecular biology & medicine·1991
Same journal

Stress proteins and cardiovascular disease.

Molecular biology & medicine·1991
See all related articles

Researchers created hybrid molecules combining fibrin-targeting antibodies with clot-dissolving enzymes. Recombinant urokinase-type plasminogen activator (scuPA) hybrids showed significantly enhanced fibrinolysis, unlike tissue plasminogen activator (tPA) hybrids.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Biotechnology

Background:

  • Developing targeted fibrinolytic agents is crucial for treating thrombotic diseases.
  • Fusion proteins offer a strategy to combine enzyme activity with specific targeting.
  • Optimization of gene expression is key for producing functional recombinant proteins.

Purpose of the Study:

  • To construct and evaluate hybrid molecules linking fibrin-binding antibody domains with plasminogen activator catalytic domains.
  • To compare the efficacy of tissue plasminogen activator (tPA) and single-chain urokinase-type plasminogen activator (scuPA) based hybrids.
  • To investigate the impact of 3' untranslated regions on fusion protein expression.

Main Methods:

  • Construction of hybrid genes encoding fusion proteins with tPA or scuPA catalytic domains and antifibrin antibody domains.

Related Experiment Videos

  • Comparison of different 3' untranslated regions (UTRs) to optimize mRNA stability and protein expression in hybridoma cells.
  • In vitro clot lysis assays and in vivo thrombolysis models to assess fibrinolytic potency and selectivity.

    • Main Results:

    • The 3' UT domain of plasminogen activator significantly reduced mRNA and protein levels compared to immunoglobulin or beta-globin 3' UT domains.
    • An antifibrin-tPA fusion protein showed similar binding and amidolytic activity but no improved clot lysis compared to tPA alone.
    • A recombinant scuPA-antifibrin antibody hybrid demonstrated a sixfold increase in potency in vitro and a 20-fold increase in a rabbit thrombolysis model.
    • Loss of fibrin-stimulated activity was observed in the antifibrin-tPA fusion protein, unlike the fibrin-independent scuPA hybrid.

    Conclusions:

    • Recombinant hybrid molecules can successfully combine plasminogen activator function with antibody-mediated targeting.
    • The scuPA-antifibrin hybrid exhibited superior fibrinolytic efficacy compared to the tPA-antifibrin hybrid, likely due to fibrin-independent activity.
    • Fusion protein design must consider the specific enzymatic properties of the plasminogen activator, such as fibrin dependence, for optimal therapeutic potential.